AAAAAA

   
Results: 1-7 |
Results: 7
MUSCARINIC AGENTS - A NEW APPROACH TO THE TREATMENT OF PSYCHOSIS
Authors: SHANNON HE BYMASTER FP BODICK NW OFFEN WW DELAPP NC PERRY KW RASMUSSEN K WARD JS WHITESITT CA FINKJENSEN A OLESEN P RASMUSSEN T SHEARDOWN M SWEDBERG M SAUERBERG P
Citation: He. Shannon et al., MUSCARINIC AGENTS - A NEW APPROACH TO THE TREATMENT OF PSYCHOSIS, Schizophrenia research, 29(1-2), 1998, pp. 158-159
THE SELECTIVE MUSCARINIC AGONIST XANOMELINE IMPROVES BOTH THE COGNITIVE DEFICITS AND BEHAVIORAL SYMPTOMS OF ALZHEIMER-DISEASE
Authors: BODICK NC OFFEN WW SHANNON HE SATTERWHITE J LUCAS R VANLIER R PAUL SM
Citation: Nc. Bodick et al., THE SELECTIVE MUSCARINIC AGONIST XANOMELINE IMPROVES BOTH THE COGNITIVE DEFICITS AND BEHAVIORAL SYMPTOMS OF ALZHEIMER-DISEASE, Alzheimer disease and associated disorders, 11, 1997, pp. 16-22
EFFECTS OF XANOMELINE, A SELECTIVE MUSCARINIC RECEPTOR AGONIST, ON COGNITIVE FUNCTION AND BEHAVIORAL SYMPTOMS IN ALZHEIMER-DISEASE
Authors: BODICK NC OFFEN WW LEVEY AI CUTLER NR GAUTHIER SG SATLIN A SHANNON HE TOLLEFSON GD RASMUSSEN K BYMASTER FP HURLEY DJ POTTER WZ PAUL SM
Citation: Nc. Bodick et al., EFFECTS OF XANOMELINE, A SELECTIVE MUSCARINIC RECEPTOR AGONIST, ON COGNITIVE FUNCTION AND BEHAVIORAL SYMPTOMS IN ALZHEIMER-DISEASE, Archives of neurology, 54(4), 1997, pp. 465-473
BRAIN PROTON MAGNETIC-RESONANCE SPECTROSCOPY (H-1-MRS) IN ALZHEIMERS-DISEASE - CHANGES AFTER TREATMENT WITH XANOMELINE, AN M-1 SELECTIVE CHOLINERGIC AGONIST
Authors: SATLIN A BODICK N OFFEN WW RENSHAW PF
Citation: A. Satlin et al., BRAIN PROTON MAGNETIC-RESONANCE SPECTROSCOPY (H-1-MRS) IN ALZHEIMERS-DISEASE - CHANGES AFTER TREATMENT WITH XANOMELINE, AN M-1 SELECTIVE CHOLINERGIC AGONIST, The American journal of psychiatry, 154(10), 1997, pp. 1459-1461
COGNITIVE IMPROVEMENT IN ALZHEIMERS-DISEASE - USE OF THE CNTB IN A TRIAL OF XANOMELINE
Authors: CUTLER NR VEROFF AE BODICK NC OFFEN WW SRAMEK JJ
Citation: Nr. Cutler et al., COGNITIVE IMPROVEMENT IN ALZHEIMERS-DISEASE - USE OF THE CNTB IN A TRIAL OF XANOMELINE, Biological psychiatry, 39(7), 1996, pp. 545-545
NIZATIDINE VERSUS PLACEBO IN GASTROESOPHAGEAL REFLUX DISEASE - A 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND-STUDY (REPRINTED FROM AMERICAN JOURNAL OF GASTROENTEROLOGY, VOL 86, PG 1735, 1991)
Authors: CLOUD ML OFFEN WW ROBINSON M
Citation: Ml. Cloud et al., NIZATIDINE VERSUS PLACEBO IN GASTROESOPHAGEAL REFLUX DISEASE - A 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND-STUDY (REPRINTED FROM AMERICAN JOURNAL OF GASTROENTEROLOGY, VOL 86, PG 1735, 1991), British journal of clinical practice, 1994, pp. 3-10
NIZATIDINE VERSUS PLACEBO IN GASTROESOPHAGEAL REFLUX DISEASE - A 6-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND COMPARISON (REPRINTED FROM DIGESTIVE DISEASES AND SCIENCES, VOL 37, PG 865, 1992)
Authors: CLOUD ML OFFEN WW
Citation: Ml. Cloud et Ww. Offen, NIZATIDINE VERSUS PLACEBO IN GASTROESOPHAGEAL REFLUX DISEASE - A 6-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND COMPARISON (REPRINTED FROM DIGESTIVE DISEASES AND SCIENCES, VOL 37, PG 865, 1992), British journal of clinical practice, 1994, pp. 11-19
Risultati: 1-7 |